Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease

European Journal of Internal Medicine

Volumn 44, Issue , 2017, Pages e28-e29

  de Lucas, María Dolores García ^a   Bueno, Beatriz Aviles ^a   Sierra, Julián Olalla ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Albuminuria; Chronic kidney disease; HbA1c; Hypoglycaemia; Liraglutide; Weight

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; LIRAGLUTIDE; GLYCOSYLATED HEMOGLOBIN;

AGED; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; KIDNEY FUNCTION; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; BODY MASS; BODY WEIGHT LOSS; COMPLICATION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; OVERWEIGHT; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 85023610873     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2017.07.020     Document Type: Letter

References (8)

1. Avogaro, A., Schernthaner, G., Achieving glycemic control in patients with type 2 diabetes and renal impairment. Acta Diabetol 50 (2013), 283–291.
2. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. For the EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015 Nov 26), 2117–2128.
3. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
4. American Diabetes Association, Standards of medical care in diabetes–2011. Diabetes Care 34 (2011), S11–S16.
5. Davies, M.J., Bergenstal, R., Bode, B., et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
6. von Scholten, B.J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T.W., et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes Metab 19 (2017), 239–247.
7. Rondinelli, M., Rossi, A., Gandolfi, A., Saponaro, F., Bucciarelli, L., Adda, G., et al. Use of Liraglutide in the real world and impact at 36 months on metabolic control, weight, lipid profile, blood pressure, heart rate, and renal function. Clin Ther 39 (2017 Jan), 159–169.
8. Skov, J., Pedersen, M., Holst, J.J., et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18 (2016), 581–589.